These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 16630993)

  • 1. Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials.
    Al-Mallah MH; Tleyjeh IM; Abdel-Latif AA; Weaver WD
    J Am Coll Cardiol; 2006 Apr; 47(8):1576-83. PubMed ID: 16630993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.
    Danchin N; Cucherat M; Thuillez C; Durand E; Kadri Z; Steg PG
    Arch Intern Med; 2006 Apr; 166(7):787-96. PubMed ID: 16606817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Coronary Artery Disease without Heart Failure in the Modern Statin Era: a Meta-Analysis of Randomized-Controlled Trials.
    Hoang V; Alam M; Addison D; Macedo F; Virani S; Birnbaum Y
    Cardiovasc Drugs Ther; 2016 Apr; 30(2):189-98. PubMed ID: 26861251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials.
    Tai C; Gan T; Zou L; Sun Y; Zhang Y; Chen W; Li J; Zhang J; Xu Y; Lu H; Xu D
    BMC Cardiovasc Disord; 2017 Oct; 17(1):257. PubMed ID: 28982370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized Trials.
    Bangalore S; Fakheri R; Toklu B; Ogedegbe G; Weintraub H; Messerli FH
    Mayo Clin Proc; 2016 Jan; 91(1):51-60. PubMed ID: 26763511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
    Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
    JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.
    Bertrand ME; Remme WJ; Fox KM; Ferrari R; Simoons ML;
    Int J Cardiol; 2007 Sep; 121(1):57-61. PubMed ID: 17270296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials.
    Bangalore S; Fakheri R; Wandel S; Toklu B; Wandel J; Messerli FH
    BMJ; 2017 Jan; 356():j4. PubMed ID: 28104622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials.
    Lakhdar R; Al-Mallah MH; Lanfear DE
    J Card Fail; 2008 Apr; 14(3):181-8. PubMed ID: 18381180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials.
    Saha SA; Molnar J; Arora RR
    J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):192-204. PubMed ID: 17875946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-Analysis of Randomized Trials on the Efficacy and Safety of Angiotensin-Converting Enzyme Inhibitors in Patients ≥65 Years of Age.
    Bavishi C; Ahmed M; Trivedi V; Khan AR; Gongora C; Bangalore S; Messerli FH
    Am J Cardiol; 2016 Nov; 118(9):1427-1436. PubMed ID: 27692594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which patients should be on renin-angiotensin system blockers after coronary surgery?
    Alassar A; Bazerbashi S; Easto R; Unsworth-White J
    Interact Cardiovasc Thorac Surg; 2014 Oct; 19(4):667-72. PubMed ID: 24997188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis: a meta-analysis.
    Tai DJ; Lim TW; James MT; Manns BJ; Tonelli M; Hemmelgarn BR;
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):623-30. PubMed ID: 20133488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis.
    Healey JS; Baranchuk A; Crystal E; Morillo CA; Garfinkle M; Yusuf S; Connolly SJ
    J Am Coll Cardiol; 2005 Jun; 45(11):1832-9. PubMed ID: 15936615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease.
    Baker WL; Coleman CI; Kluger J; Reinhart KM; Talati R; Quercia R; Phung OJ; White CM
    Ann Intern Med; 2009 Dec; 151(12):861-71. PubMed ID: 20008762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ACE Inhibitors Versus ARBs in Patients With NSTEMI With Preserved LV Systolic Function Who Underwent PCI With New Generation Drug-Eluting Stents.
    Kim YH; Her AY; Jeong MH; Kim BK; Hong SJ; Kim S; Ahn CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Angiology; 2020 Feb; 71(2):139-149. PubMed ID: 31694385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients >or=65 years of age with heart failure and preserved left ventricular systolic function.
    Shah R; Wang Y; Foody JM
    Am J Cardiol; 2008 Jan; 101(2):217-22. PubMed ID: 18178410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACE inhibitors in heart failure: what more do we need to know?
    Demers C; Mody A; Teo KK; McKelvie RS
    Am J Cardiovasc Drugs; 2005; 5(6):351-9. PubMed ID: 16259523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sudden cardiac death in patients with stable coronary artery disease and preserved left ventricular systolic function.
    Hsia J; Jablonski KA; Rice MM; Sabatine MS; Zabalgoitia M; Maggioni A; Cuddy TE; Domanski MJ; Geller NL; Flaker G; Solomon S; Omland T; Rouleau JL;
    Am J Cardiol; 2008 Feb; 101(4):457-61. PubMed ID: 18312757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.